Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue

Biomedical Chromatography

Volumn 17, Issue 7, 2003, Pages 458-464

  Sparidans, Rolf W ^a   Silvertand, Linda ^a   Dost, Frits ^a   Rothbarth, Joost ^b   Mulder, Gerard J ^c   Schellens, Jan H M ^a   Beijnen, Jos H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biological matrix; Isolated liver perfusion; Nitrogen mustard; Stability; Ultraviolet detection

Indexed keywords

NITROGEN; RATS; TUMORS;

BIOLOGICAL MATRIXES; ISOLATED LIVER PERFUSION; LIVER PERFUSION; LIVER TISSUE; MELPHALAN; NITROGEN MUSTARDS; SIMPLE++; TUMOUR TISSUE; ULTRA VIOLET DETECTION; ULTRAVIOLET DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENT; MELPHALAN; METHANOL; PROPYL PARABEN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG ISOLATION; DRUG STABILITY; DRUG TISSUE LEVEL; ISOLATED LIVER; LIVER; LIVER PERFUSION; LOW TEMPERATURE; MALE; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; STANDARDIZATION; TISSUE PRESERVATION; ULTRAVIOLET RADIATION;

EID: 0242525078     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.273     Document Type: Article

References (25)

1. Adair CG, Burns DT, Crockard AD, Desai ZR and Harriott M. Modified extraction and chromatography for the measurement of plasma melphalan by ion-pair high-performance liquid chromatography. Journal of Chromatography 1984; 336: 429.
2. Ahmed AE and Hsu T-F. Quantitative analysis of melphalan and its major hydrolysate in patients and animals by reversed-phase high-performance liquid chromatography. Journal of Chromatography 1981; 222: 453.
3. Bergel F and Stock JA. Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines. Journal of the Chemical Society 1954; 76: 2409.
4. Bosanquet AG and Gilby ED. Measurement of plasma melphalan at therapeutic concentrations using isocratic high-performance liquid chromatography. Journal of Chromatography 1982; 232: 345.
5. Chang SY, Alberts DS, Melnick LR, Walson PD and Salmon SE. High-pressure liquid chromatographic analysis of melphalan in plasma. Journal of Pharmaceutical Science 1978; 67: 679.
6. Cummings J, McLellan A and Smyth JF. Determination of reactive nitrogen mustard anticancer drugs in plasma by high-performance liquid chromatography using derivatization. Analytical Chemistry 1991; 63: 1514.
7. Davies ID, Allanson JP and Causon RC. Rapid determination of the anti-cancer drug melphalan (Alkeran™) in human serum and plasma by automated solid phase extraction and liquid chromatography tandem mass spectrometry. Chromatographia 2000; 52: S-92.
8. Egan CM, Jones CR and McCluskey M. Method for the measurement of melphalan in biological samples by high-performance liquid chromatography. Journal of Chromatography 1981; 224: 338.
9. Ehrson H, Eksborg S and Lindfors A. Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. Journal of Chromatography 1986; 380: 222.
10. Kato Y, Kaneko H, Matsushita T, Inamori K, Egi S, Togawa A, Yokoyama T and Mohri K. Direct injection of melphalan in plasma using column-switching high-performance liquid chromatography. Therapeutic Drug. Monitoring 1992; 14: 66.
11. Marquet RL, Westbroek DL and Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. International Journal of Cancer 1984; 33: 689.
12. Osterheld HKO, Musch E, von Unruh GE, Loos U, Rauschecker H and Mülenbruch BJ. Cancer Chemotherapy and Pharmacology 1988; 21: 156.
13. Pinguet FP, Joulia JM, Martel P, Grosse PY, Astre C and Bressolle F. High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. Journal of Chromatography B 1996; 686: 43.
14. Rosing H, Man WY, Doyle E, Bult A and Beijnen JH. Bioanalytical chromatographic method validation. A review of current practices and procedures. Journal of Liquid Chromatography and Related Technology 2000; 23: 329.
15. Rothbarth J, Sparidans RW, Beijnen JH, Schultze Kool LJ, Putter H, van de Velde CJH and Mulder GJ. Reduce liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. Journal of Pharmacology and Experimental Therapy 2002; 303: 736.
16. Samuels BL and Bitran JD. High-dose intravenous melphalan: a review. Journal of Clinical Oncology 1995; 13: 1786.
17. Sarosy G, Leyland-Jones B, Soochan P and Cheson BD. The systemic administration of intravenous melphalan. Journal of Clinical Oncology 1988; 6: 1768.
18. Shah VP, Midha KK, Dighe S, McGliveray IJ, Skelly JP, Jacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA and Spector S. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Journal of Pharmaceutical Science 1992; 81: 309.
19. Silvestro L, Viano I, Baiocchi C, Saini S, Marmont F and Ferro R. Quantitation of melphalan in plasma of patients by reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 1991; 563: 443.
20. Springolo V, Borella F, Finardi GP, Gatti MT and Coppi G. High-performace liquid chromatographic determination of m-bis(chloroethyl)aminophenyl-L-alanine in plasma. Journal of Chromatography 1989; 490: 224.
21. Stout SA and Riley CM. The hydrolysis of L-phenylalanine mustard (melphalan). International Journal of Pharmaceutics 1985; 24: 193.
22. Sweeney DJ, Greig NH and Rapoport SI. High-performance liquid chromatographic analysis of melphalan in plasma, brain and peripheral tissue by o-phthalaldehyde derivatization and fluorescence detection. Journal of Chromatography 1985; 339: 434.
23. Vahrmeijer AL, van Dierendonk JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ and van de Velde CJ. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. British Journal of Cancer 2000; 83: 1539.
24. Vey N, De Prijck B, Faucher C, Stoppa AM, Sainty D, Lafage M, Bouabdallay R, Chabannon C, Camerlo J, Gastout JA, Maraninchi D and Blaise D. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone Marrow Transplantation 1996; 18: 495,
25. Wu Z-Y, Thompson ML, Roberts MS, Addison RS, Cannell GR, Grabs AJ and Smithers BM. High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. Journal of Chromatography B 1995; 673: 267.